Cancer Education and Research Institute
Worldwide Access to High-Quality Care, Research, and Education

United Nations, UNIATF Award 2019 Recipient

DONATE to support our programs
  • Home
    • About us >
      • About the Founder
    • Annual Reports and Media Kit
    • News Room >
      • CERI Press Releases 2022
      • CERI Press Releases 2021
      • Press Releases 2020
      • Press Releases 2019
      • Press Releases 2018
      • Press Releases 2017
      • Press Releases 2016
      • Press Releases 2015
      • Press Releases 2014
      • Press Releases 2013
    • Testimonials
  • MULTI-LANGUAGE CANCER BLOG
  • For Patients
    • CERI Personalized Patient Program™
    • All about cancer
    • Cancer Education
    • Watch Our Cancer Videos >
      • Ovarian cancer diagnosis
    • Our Publications >
      • Read CERI Simplified Cancer Research Articles
    • Cancer Types
    • Cancer detection and cancer treatment
    • Cancer Awareness Months
  • Events
  • Donate
    • Sponsorship levels
    • Membership
    • Become A Sponsor
    • Shop at CERI
    • Volunteer
    • Become a CERI Board Member
  • Contact us
Tweet
Follow @canceredinst

Cancer Education and Research Institute (CERI)'s Cancer Education Programs 

Our Team of cancer experts at Cancer Education and Research Institute® (CERI)'s, formerly Cancer Research Simplified, provides you with the most reliable, most up-to-date, and simplified cancer information available. Our educational programs quickly became trusted and highly sought after worldwide.  

CERI strongly stands behind the importance of cancer patient empowerment and is a worldwide leading source for simplified, multi-language cancer education.  Knowledge is power and empowerment is the key for greater treatment success, early diagnosis, as well as cancer prevention.  

For any questions or requests, please submit your inquiry at our CERI Personalized Patient Program™ page.

Breast Cancer Treatments 

Aygün Sahin, MSc, PhD  | CEO and Cancer Lead, Cancer Education and Research Institute (CERI)
This page will be updated regularly!

FDA approved treatments for Breast Cancer

FDA approvals in 2021 
  • July 26, 2021: The FDA approved pembrolizumab for high-risk early-stage triple-negative breast cancer
​The Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) for high-risk, early-stage, triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.

The FDA also granted regular approval to pembrolizumab in combination with chemotherapy for patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 as determined by an FDA approved test.
FDA granted accelerated approval to pembrolizumab for this indication in November 2020.

The results of each of the clinical trials are as follow:

Pathological complete response (pCR) rate:
Patients who received pembrolizumab in combination with chemotherapy:  63% (95% CI: 59.5, 66.4)
Patients who received chemotherapy alone: 56% (95% CI: 50.6, 60.6)

Event free survival (EFS):
Patients who received pembrolizumab in combination with chemotherapy:  123% (16% CI: 59.5, 66.4)
Patients who received chemotherapy alone: 93% (24% CI: 50.6, 60.6)
HR 0.63; 95% CI: 0.48, 0.82; p=0.00031

Breast Cancer Treatment | Cancer Education and Research Institute (CERI)
Breast Cancer Treatment | Cancer Education and Research Institute (CERI)

FDA approvals in 2020 
  • December 16, 2020: FDA approved MARGENZA for treatment of metastatic HER2-positive breast cancer
​The Food and Drug Administration (FDA) approved MARGENZA (injection) for adult patients with previously treated metastatic HER2-positive breast cancer.
Learn more here.
HER2-positive breast cancer | Cancer Education and Research Institute (CERI)
  • May 20, 2020:  FDA approved diagnostic imaging agent, Cerianna, for estrogen receptor (ER)-positive patients with breast cancer
The Food and Drug Administration (FDA) approved CERIANNA (fluoroestradiol F 18) as a drug for the visual detection of estrogen receptor (ER)-positive lesions in addition to tissue biopsy in patients with recurrent or metastatic breast cancer.
Learn more here.

Estrogen receptor ER-positive breast cancer treatment | Cancer Education and Research Institute (CERI)

#breastcancer #breastcancertreatment #estrogenreceptorpositivebreastcancer #ERpostitivebreastcancer #BC #BCSM #fda #fdaapproved #fdaapproval #today #keytruda

Resources: 
  1. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-high-risk-early-stage-triple-negative-breast-cancer?utm_medium=email&utm_source=govdelivery  (accessed on July 27, 2021)
  2. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-margenza (accessed on July 27, 2021)
  3. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trial-snapshot-cerianna (accessed on July 27, 2021)

Click here to learn everything you need to know about breast cancer and how to do breast self-examination (BSE) on our Youtube channel.


You might also like:


Disclaimer: We can not assume responsibility of misinterpretation of content.

    Help us to serve you better!

Submit
Yes, I'd like to help CERI continue saving lives!

Make a Monthly Contribution

Cancer Education and Research Institute® (formerly Cancer Research Simplified) is an independent 501(c)(3) non-profit organization.
Homepage 
Türkçe
Deutsch

About us
Meet the Founder
Meet the Team

News Room
Media Kit
Press Releases 
Watch Cancer Videos
Kanser videolarını izle
Krebs Videos ansehen
Cancer Resources

CERI Youth Program

Events

Shop at CERI


Ways to Help
Donate
Volunteer
Become A Sponsor

Blog
Blog-Deutsch
Blog-Türkçe
Blog-Afrikaans
Blog-Espanol
Blog-Italiano
Blog-Russkij
Blog-Portugues


Cancer Awareness Months



Stay Involved
Facebook
Twitter
Youtube
LinkedIn

Testimonials

Jobs

Contact Us
Cancer Research Simplified Homepage
Terms of Service
Privacy Policy
Picture
Picture
Picture
Picture
Picture
Picture
Picture
Picture
Picture
Copyright © 2013-2023 Cancer Education and Research Institute®. All Rights Reserved. 
Sitemizdeki yazı, video ve resim her hakkı saklıdır. İzinsiz, kaynak gösterilmeden kullanılamaz.  
Alle Rechte vorbehalten.                             

Powered by Cancer Education and Research Institute®